Wedbush Reiterates Outperform on United Therapeutics, Maintains $308 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Liana Moussatos has reiterated an Outperform rating on United Therapeutics (NASDAQ:UTHR), maintaining a price target of $308.
February 22, 2024 | 1:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Liana Moussatos reiterates an Outperform rating on United Therapeutics, with a maintained price target of $308.
The reiteration of an Outperform rating by a reputable analyst, along with a high price target, suggests a strong bullish sentiment towards United Therapeutics. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100